By Professor Ric Day

Journal articles

Day RO; Williams KM; Campbell TJ, 1998, 'The death of a normal healthy volunteer in a human research project: implications for Australian clinical research', Medical Journal of Australia, 168, pp. 449 - 451, http://dx.doi.org/10.5694/j.1326-5377.1998.tb139026.x

Day R; Mant A; Whicker S; Primrose J, 1997, 'Quality assessment in therapeutics: Antibiotic use', Clinical Pharmacology and Therapeutics, 61, pp. 214

Williams KM; Turner J; Geisslinger G; Day RO, 1997, 'The suction blister as an in vivo model of inflammation: Interblister variability and preliminary studies of the disposition of methotrexate', Clinical Pharmacology and Therapeutics, 61, pp. 160

Walker JS; Sheather-Reid RB; Carmody JJ; Vial JH; Day RO, 1997, 'Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis: Support for the concept of 'responders' and 'nonresponders'', Arthritis and Rheumatism, 40, pp. 1944 - 1954, http://dx.doi.org/10.1002/art.1780401105

Day R; Mant A; Whicker S; Primrose J, 1997, 'Quality assessment in therapeutics: Antibiotic use.', CLINICAL PHARMACOLOGY & THERAPEUTICS, 61, pp. PII79 - PII79, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1997WJ68400306&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bellamy N; Bachmeier C; Brooks PM; Browne CD; Cohen ML; March L; Conaghan PG; Day RO; Campbell J, 1997, 'Osteoarthritis antirheumatic drug trials: Effects of a standardized instructional videotape on the reliability of observer-dependent outcome measures', Inflammopharmacology, 5, pp. 285 - 295, http://dx.doi.org/10.1007/s10787-997-0006-9

Day RE; Gero AM, 1997, 'Stimulated transport of hypoxanthine in Crithidia luciliae: Relationship to purine stress', Parasitology, 114, pp. 19 - 27, http://dx.doi.org/10.1017/S003118209600827X

Lehmann T; Day RO; Brooks PM, 1997, 'Toxicity of antirheumatic drugs', Medical Journal of Australia, 166, pp. 378 - 383, http://dx.doi.org/10.5694/j.1326-5377.1997.tb123171.x

Birkett DJ; Miners JO; Valente KJ; Lillywhite KJ; Day RO, 1997, '1-Methylxanthine Derived from Caffeine as a Pharmacodynamic Probe of', British Journal of Clinical Pharmacology, pp. 197 - 200

Conaghan PG; Crotty M; Oh E; Day RO; Brooks PM, 1997, 'Anti-rheumatic drug-prescribing behaviour of australasian rheumatologists 1984-1994.', British Journal of Rheumatology, pp. 487 - 490

Shackel NA; Day RO; Kellett B; Brooks PM, 1997, 'Copper-salicylate gel for pain relief in osteoarthritis - a randomised controlled trial.', Medical Journal of Australia, 167, pp. 134 - 136

Donnelly R; Williams KM; Baker A; Badcock CA; Day RO; Seale JP, 1997, 'Effects of budesonide and fluticasoue on 24-hour plasma cortisol: A dose-response study.', American Journal of Respiratory and Critical Care Medicine, 156, pp. 1746 - 1751, http://dx.doi.org/10.1164/ajrccm.156.6.9703003

Walker JS; Sheather-Reid RB; Carmody JJ; Vial JH; Day RO, 1997, 'Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis - support', Arthritis Care & Research, pp. 1944 - 1954

Walker JS; Sheather-Reid RB; Carmody JJ; Vial JH; Day RO, 1997, 'Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis: support for the concept of "responders" and "nonresponders".', Arthritis Rheum, 40, pp. 1944 - 1954, http://dx.doi.org/10.1002/art.1780401105

Quinn DE; Wodak AD; Day RO, 1997, 'Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.', Clinical Pharmacokinetics, pp. 344 - 400

Wodak AD; Quinn DE; Day RO, 1997, 'Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.', Clinical Pharmacokinetics, pp. 344 - 400

Quinn DE; Wodak AD; Day RO, 1997, 'Pharmocokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users', Clinical Pharmacokinetics, pp. 344 - 400

Lehmann T; Day RO; Brooks PM, 1997, 'Rheumatology 12. Toxicity of antirheumatic', Medical Journal of Australia, 166, pp. 378 - 383

Gero AM; Day RE; Hall ST, 1997, 'Stimulated transport of adenosine, guanosine and hypoxanthine in Crithidia luculiae: Metabolic machinery in which the parasite has a distinct advantage over the host', International Journal for Parasitology, pp. 241 - 249

Day RO; Williams KM; Geisslinger G, 1996, 'Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations - Reply', JOURNAL OF RHEUMATOLOGY, 23, pp. 1827 - 1828, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1996VL78300035&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Handel ML; Watts CKW; Sivertsen S; Day RO; Sutherland RL, 1996, 'D-penicillamine causes free radical-dependent inactivation of activator protein-1 DNA binding', Molecular Pharmacology, 50, pp. 501 - 505

Carey DL; Day RO; Bowden FJ, 1996, 'Common drug interactions in HIV medicine', MEDICAL JOURNAL OF AUSTRALIA, 164, pp. 605 - 606, http://dx.doi.org/10.5694/j.1326-5377.1996.tb122205.x

Carey DL; Day RO; Bowden FJ, 1996, 'Managing HIV. Common drug interactions in HIV medicine.', Med J Aust, 164, pp. 605 - 606, https://www.ncbi.nlm.nih.gov/pubmed/8637465

Walker JS; Day RO; Moore UJ; Marsh VR; Ashton CH; Seymour RA, 1996, 'Experimental pain techniques [2]', British Journal of Clinical Pharmacology, 41, pp. 349 - 350

Simkin PA; Bassett JE; Lapicque F; Bertin P; Netter P; Day RO; Williams KM; Geisslinger G, 1996, 'Naproxen concentration in plasma and synovial fluid and effects on prostanoid concentrations [1]', Journal of Rheumatology, 23, pp. 1826 - 1828

Handel ML; Watts CG; Silversten S; Day RO; Sutherland RL, 1996, 'D-Penicillamine causes free-radical-dependent inactivation of activator protein-1 DNA binding', Molecular Pharmacology, pp. 1 - 5

Day RO; Brown S; Weekes LM, 1996, 'Drug committees - the key to quality use of medicines?', Australian Journal of Hospital Pharmacy, pp. 622 - 623

Walker JW; Lockton A; Nguyen L; Day RO, 1996, 'Effect of single and multiple doses of ibuprofen in chronic spinal pain patients', Analgesia, 2, pp. 93 - 101

Walker JW; Chandler A; Wilson J; Binder W; Day RO, 1996, 'Effect of u-opioids morphine and buprenorphine on the development of adjuvant arthritis in rats', Inflammation Research, pp. 557 - 563

Johnson AG; Nguyen TM; Day RO, 1996, 'Evaluation of the Takeda TM-2420 in the Elderly', Journal of Hypertension, 10, pp. 61 - 61

Walker JW; Day RO, 1996, 'Experimental pain techniques', British Journal of Clinical Pharmacology, pp. 246 - 246

Tett S; Day RO; Cutler D, 1996, 'Hydroxychloroquine relative bioavailability: within subject reproducibility', British Journal of Clinical Pharmacology, pp. 244 - 246

Carey DL; Day RO; Bowden FJ, 1996, 'Managing HIV, Quick reference:drug interactions. Common drug interactions in HIV medicine', Medical Journal of Australia, 164, pp. 605 - 606

Mcmanus PA; Primrose JG; Henry D; Birkett DJ; Lindner J; Day RO, 1996, 'Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994, A report from the Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory', Medical Journal of Australia, 164, pp. 589 - 592

Graham GG; Day RO; Wong H; Mclachlan AJ; Bergendal L; Miners JO; Birkett DJ, 1996, 'Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects', British Journal of Clinical Pharmacology, pp. 299 - 304

Johnson AG; Nguyen TM; Owe-Young R; Williamson DJ; Day RO, 1996, 'Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-I', Journal of Hypertension, 10, pp. 257 - 261

Day RO; Francis H; Vial J; Geisslinger G; Williams KM, 1995, 'Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations', Journal of Rheumatology, 22, pp. 2295 - 2303

BOERS M; BROOKS P; TUGWELL P; BAKER P; BOMBARDIER C; DAY R; DRUMMOND M; VANDERLINDEN S; OBRIEN B; SILMAN A; STRAND V; WELLS G, 1995, 'OUTCOME MEASURES IN RHEUMATOID-ARTHRITIS CLINICAL-TRIALS - ACKNOWLEDGMENTS', JOURNAL OF RHEUMATOLOGY, 22, pp. 1433 - 1433, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1995RG24600046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Handel ML; Watts CKW; DeFazio A; Day RO; Sutherland RL, 1995, 'Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos', Proceedings of the National Academy of Sciences of the United States of America, 92, pp. 4497 - 4501, http://dx.doi.org/10.1073/pnas.92.10.4497

BROOKS PM; DAY RO, 1995, 'TOXICITY OF ANTIRHEUMATIC DRUGS', JOURNAL OF RHEUMATOLOGY, 22, pp. 998 - 999

JOHNSON AG; NGUYEN TV; DAY RO, 1995, 'NONSTEROIDAL ANTIINFLAMMATORY DRUGS AND HIGH BLOOD-PRESSURE - RESPONSE', ANNALS OF INTERNAL MEDICINE, 122, pp. 397 - 397, http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00028

Conaghan PG; Quinn DI; Brooks PM; Day RO, 1995, 'Hazards of low dose methotrexate', Australian and New Zealand Journal of Medicine, 25, pp. 670 - 673, http://dx.doi.org/10.1111/j.1445-5994.1995.tb02851.x

Johnson AG; Quinn DI; Day RO, 1995, 'Non-steroidal anti-inflammatory drugs', Medical Journal of Australia, 163, pp. 155 - 158, http://dx.doi.org/10.5694/j.1326-5377.1995.tb127972.x

Radack K; Johnson AG; Nguyen TV; Day RO, 1995, 'Nonsteroidal anti-inflammatory drugs and high blood pressure [8]', Annals of Internal Medicine, 122, pp. 397, http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00027

Brooks PM; Day R, 1995, 'Treatment issues', Bailliere's Clinical Rheumatology, 9, pp. 231 - 245, http://dx.doi.org/10.1016/S0950-3579(05)80158-X

Brooks PM; Day RO, 1995, 'Workshop report - Part 1: Toxicity of antirheumatic drugs', Journal of Rheumatology, 22, pp. 998 - 999

Day RO; Quinn DE; Conaghan PG; Tett S, 1995, 'Adverse drug reactions and their measurement in the rheumatic diseases', Journal of Rheumatology, pp. 983 - 988

Quinn DE; Day RO, 1995, 'Clinically Important Drug Interactions.', Drug Safety, 12, pp. 393 - 452

Quinn DE; Day RO, 1995, 'Drug interactions of clinical importance: an updated guide', Drug Safety, 12, pp. 393 - 452

Johnson AG; Quinn DE; Day RO, 1995, 'Non-steroidal anti-inflammatory drugs', Medical Journal of Australia, 163, pp. 155 - 158

Back to profile page